Verdiva Bio

Verdiva Bio is a clinical-stage biotech firm creating obesity and cardiometabolic therapies. Lead candidate VRB-101 is a weekly oral GLP1 agonist.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2024